Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
at what point will NWBO get a name for constantly pulling out of conferences? Seriously. This must be a huge nuisance to the glioblastoma-drugdevelopment conference organization they pulled out 4 days before it started, people are paying admittance.
ooh yeah, it happens that people forget its the other way around.
The same for crypto as in Casinos always place your money on the color or number where the ball will fall on next, people seem to forget that simple rule lol
wrong
NWBO needs continuous FDA permission to sell DCVAX L as compassionate treatment, which we know for a few days now is exactly what they are doing, has just started up, in Sawston. FDA has seen the data for sure, combine the two and you know what time it is.
that is correct
Moreover, the FDA and the MHRA have permitted the continuation of the compassionate sales of DCVAX L in Sawston after the FDA has become aware of the unblinded data. It would be beyond bizarre if in the near future the FDA would turn around and disapprove DCVAXL after the BLA is submitted.
you can only say that you are glad that you didnt invest all after topline data+publication or am I wrong?
Your explanation makes sense. If the presentation was always intended prior to TLD / journal as we have seen Dr Liau's last year then they would have not canceled. Something very short notice came up so they had to cancel and if I had to guess it is NEJM letting NWBO know they had to move the publication to another time frame.
Exactly
You have to give Bosch a bit more credit then that he would not have confounded the trial results, he is NWBOs CTO and co author!
Let’s say they planned max 2 weeks between TLD and the journal and Bosch just after TLD. It would not surprise me if NEJM called them yesterday and told them they have to move the publication to half feb. In that case it would leave them no choice to cancel Bosch. If the publication were not ready yet then they would have known that weeks ago and cancelled a lot sooner. IMO
well I dont want to be negative but how much time before the placeholder was canceled for the dr Liau talk in nov 2020? 3,4 days?
Thanks that is true
mmm it could also be a small hick up with NEJM and not with NWBO this time
yup I think scenario 1 is most likely for peat sake let it be a small delay
looks like it, freaking unbelievable
jeeezzzzzzzzzz
yes he pulled out
https://glioblastoma-drugdevelopment.com/speaker/marnix-bosch-2/
Title and time now stripped from his speaking slot.
another placeholder removed?
hahahah lol I would not go that far but I happen to be called a fossil but that probably has more to do with my know it all savvy kids
One thing we can be sure of is the FDA has seen trial data and if they did not like the data they would have stopped/warned NWBO from proceeding with the compassionate treatment as what they are doing now, full steam ahead.
What signal would the FDA, UK/EMA give if they later this year would dismiss DCVAX L to patients that have been treated.
Like I said before
this month 80% or max Feb 95%
80% in Jan
95% in feb
100% in march
But end January or first week Feb
many have asked you questions that you have left unanswered so Im a bit reluctant to answer your question for that reason. But ok.
There are certain circles that have proven to be very reliable to me even more so than LG. And that is because LG has not been that reliable over the years. So firsthand info does not need to be super reliable perse.
But my sources are the second of your equation and your conclusion that such is thus less trustworthy is not my experience.
I Cant say anything more than I already did other than Im not just saying that. And I fully understand you take it with a grain of salt
I think the delay of results is due to the delay of the publication which is in turn due to covid. I have heard (reliable outside this board) its very very close (publication).
Since the publication is not in the hands of NWBO it would be a complete waste of time if meanwhile, NWBO had not worked on BLA and expedited approval but in what phase that is I have no idea.
I dont understand what you are asking
I don’t think they have filed a BLA either. I do believe they have drafted the BLA and are almost ready to submit
thanks dec 2016 how time flies
Challenges of designing & evaluating clinical trials for immunotherapies in the GBM field is nothing more and nothing less than what we have heard Dr. Liau discussing last year and what has been discussed in The Lancet journal article in Oct.
Simply put:
For a trial in a lethal disease such as GBM you just cant from an ethical standpoint maintain a placebo control arm especially when the treatment is working. In other words, you can not let the placebo die so the statistics will benefit better.
And of course that's a challenge for its new
yes I agree NWBO should improve its communication.
But Im 100% convinced they will make it up with us very soon!